ArticleRadiologia brasileira
The ratio between the whole-body and primary tumor burden, measured on
Article in Radiologia brasileira. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Pseudotime-Based derivation of a PET-Based metabolic progression index for prognostic stratification in Extensive-Stage SCLC.Annals of nuclear medicine · 2026Article
- Article
- Volumetric parameters of the primary tumor and whole-body tumor burden derived from baselineEuropean journal of hybrid imaging · 2022Article
- Classification of non-small cell lung cancer by histologic subtype using deep learning in public and private data sets of computed tomography images.Radiologia brasileiraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether the whole-body tumor burden, as quantified by MATERIALS AND
methodsThis was a prospective study in which we evaluated
results
conclusionThe wbTLG/tuTLG ratio is an independent prognostic indicator of OS in advanced-stage NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.